| The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group N Leung, F Bridoux, V Batuman, A Chaidos, P Cockwell, VD D’Agati, ... Nature Reviews Nephrology 15 (1), 45-59, 2019 | 457 | 2019 |
| Tazemetostat for patients with relapsed or refractory follicular lymphoma: an open-label, single-arm, multicentre, phase 2 trial F Morschhauser, H Tilly, A Chaidos, P McKay, T Phillips, S Assouline, ... The Lancet Oncology 21 (11), 1433-1442, 2020 | 392 | 2020 |
| Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ... The Lancet 393 (10168), 253-264, 2019 | 242 | 2019 |
| Potent antimyeloma activity of the novel bromodomain inhibitors I-BET151 and I-BET762 A Chaidos, V Caputo, K Gouvedenou, B Liu, I Marigo, MS Chaudhry, ... Blood, The Journal of the American Society of Hematology 123 (5), 697-705, 2014 | 222 | 2014 |
| Inhibition of bromodomain and extra-terminal proteins (BET) as a potential therapeutic approach in haematological malignancies: emerging preclinical and clinical evidence A Chaidos, V Caputo, A Karadimitris Therapeutic advances in hematology 6 (3), 128-141, 2015 | 185 | 2015 |
| Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune‐mediated pathogenesis H De Lavallade, S Punnialingam, D Milojkovic, M Bua, JS Khorashad, ... British journal of haematology 141 (5), 745-747, 2008 | 182 | 2008 |
| Poly (ADP-ribose) polymerase family member 14 (PARP14) is a novel effector of the JNK2-dependent pro-survival signal in multiple myeloma A Barbarulo, V Iansante, A Chaidos, K Naresh, A Rahemtulla, G Franzoso, ... Oncogene 32 (36), 4231-4242, 2013 | 181 | 2013 |
| Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation A Chaidos, S Patterson, R Szydlo, MS Chaudhry, F Dazzi, E Kanfer, ... Blood, The Journal of the American Society of Hematology 119 (21), 5030-5036, 2012 | 166 | 2012 |
| Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma A Chaidos, CP Barnes, G Cowan, PC May, V Melo, E Hatjiharissi, ... Blood, The Journal of the American Society of Hematology 121 (2), 318-328, 2013 | 162 | 2013 |
| Perturbation of fetal liver hematopoietic stem and progenitor cell development by trisomy 21 A Roy, G Cowan, AJ Mead, S Filippi, G Bohn, A Chaidos, O Tunstall, ... Proceedings of the National Academy of Sciences 109 (43), 17579-17584, 2012 | 161 | 2012 |
| Glycosylphosphatidylinositol-specific, CD1d-restricted T cells in paroxysmal nocturnal hemoglobinuria L Gargiulo, M Papaioannou, M Sica, G Talini, A Chaidos, B Richichi, ... Blood, The Journal of the American Society of Hematology 121 (14), 2753-2761, 2013 | 111 | 2013 |
| Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-target inhibition of kinases important for cell signaling H De Lavallade, A Khoder, M Hart, A Sarvaria, T Sekine, A Alsuliman, ... Blood, The Journal of the American Society of Hematology 122 (2), 227-238, 2013 | 106 | 2013 |
| Serum ferritin, transferrin and soluble transferrin receptor levels in multiple sclerosis patients C Sfagos, AC Makis, A Chaidos, EC Hatzimichael, A Dalamaga, K Kosma, ... Multiple Sclerosis Journal 11 (3), 272-275, 2005 | 103 | 2005 |
| Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone V Alymara, D Bourantas, A Chaidos, P Bouranta, M Gouva, A Vassou, ... The Hematology Journal 5 (6), 475-479, 2004 | 95 | 2004 |
| Interim report from a phase 2 multicenter study of tazemetostat, an EZH2 inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin Lymphomas F Morschhauser, G Salles, P McKay, H Tilly, A Schmitt, J Gerecitano, ... Hematological Oncology 35, 24-25, 2017 | 82 | 2017 |
| Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells HW Auner, AM Moody, TH Ward, M Kraus, E Milan, P May, A Chaidos, ... PloS one 8 (9), e74415, 2013 | 66 | 2013 |
| Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease A Ersek, K Xu, A Antonopoulos, TD Butters, AE Santo, Y Vattakuzhi, ... The Journal of clinical investigation 125 (6), 2279-2292, 2015 | 52 | 2015 |
| Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation HW Auner, R Szydlo, A Rone, A Chaidos, C Giles, E Kanfer, ... Leukemia & lymphoma 54 (10), 2200-2204, 2013 | 52 | 2013 |
| Impact of route and adequacy of nutritional intake on outcomes of allogeneic haematopoietic cell transplantation for haematologic malignancies J Beckerson, RM Szydlo, M Hickson, CE Mactier, AJ Innes, IH Gabriel, ... Clinical nutrition 38 (2), 738-744, 2019 | 49 | 2019 |
| Recombinant human erythropoietin for the treatment of anaemia in patients with chronic idiopathic myelofibrosis SN Tsiara, A Chaidos, LK Bourantas, HD Kapsali, KL Bourantas Acta Haematologica 117 (3), 156-161, 2007 | 47 | 2007 |
